| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (NCT04815356) | National Cancer Institute (NCI) | 2022-05-23 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia (NCT05388123) | Scripps Health | 2022-03-02 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (NCT05645744) | Mustang Bio | 2021-09-29 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745) | Newave Pharmaceutical Inc | 2021-07-19 |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant (NCT04322383) | National Cancer Institute (NCI) | 2021-01-07 |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL (NCT04324112) | National Cancer Institute (NCI) | 2020-10-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (NCT04125290) | AstraZeneca | 2019-12-09 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (NCT03805932) | National Cancer Institute (NCI) | 2019-10-03 |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (NCT03410875) | Memorial Sloan Kettering Cancer Center | 2018-02-09 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358) | Alexey Danilov, MD | 2017-07-17 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. (NCT02012231) | Fore Biotherapeutics | 2014-02-01 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (NCT01841723) | National Cancer Institute (NCI) | 2013-04-30 |
| Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease (NCT01720758) | HaEmek Medical Center, Israel | 2012-11-01 |
| Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study (NCT02883946) | CHU de Reims | 2012-06-01 |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (NCT01059786) | National Cancer Institute (NCI) | 2010-07-01 |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia (NCT00924040) | National Cancer Institute (NCI) | 2009-02-01 |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia (NCT00923013) | National Cancer Institute (NCI) | 2008-10-20 |
| A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia (NCT00586924) | MedImmune LLC | 2007-05-10 |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease (NCT00462189) | Cambridge Antibody Technology | 2007-04-01 |
| LMB-2 to Treat Hairy Cell Leukemia (NCT00321555) | National Cancer Institute (NCI) | 2006-05-02 |
| Therapy Optimisation for the Treatment of Hairy Cell Leukemia (NCT02131753) | University of Giessen | 2004-05-01 |
| Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer (NCT00898079) | Children's Oncology Group | 2003-10-13 |
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia (NCT00001567) | National Cancer Institute (NCI) | 1997-01-01 |